Evaluation of Glutathione peroxidase activity and Angiotensin II as monitoring biomarkers of long-term therapy in Iraqi patients with prostate cancer
DOI:
https://doi.org/10.31989/bchd.v9i3.1941Abstract
Introduction: Prostate cancer is the second most common cancer in men worldwide. The current therapeutic approaches include the use of hormonal manipulation, particularly agents like Goserelin acetate and Bicalutamide.
Objective: The present study sought to explore the combination of Goserelin acetate and Bicalutamide therapy on aldosterone, angiotensin II, glutathione, and glutathione peroxidase activity in prostate cancer patients, before treatment and after three years of therapy.
Methods: A total of 100 participants were collected, including 30 prostate cancer patients before treatment (G2), 40 participants were collected after treatment with Goserelin acetate as monotherapy (G4), and 30 participants with Goserelin acetate and Bicalutamide as combine therapy (G5).
Results: The results showed significantly in all parameters when compared to newly diagnosed except GSH in monotherapy. Notably, ROC curve analysis demonstrated an excellent discriminative ability, with an AUC of 0.914 for G4 and 1.000 for G5 in Ang II hormone, also in GSH-Px enzyme activity was 1.000 for group G4 and 0.968 for group G5. This highlighting Ang II and GSH-Px activity as a highly sensitive and specific monitoring biomarker for long-term treatment response assessment.
Conclusion: This study highlights a strong association between alterations in steroid hormones and prostate cancer progression under combination hormonal therapy, suggesting their potential role as biomarkers for monitoring therapeutic efficacy.
Novelty of the Study։ This study provides the first comparative evaluation of Glutathione peroxidase activity and Angiotensin II as monitoring biomarkers of long-term therapy in Iraqi patients with prostate cancer.
Keywords: Aldosterone, Angiotensin II, Glutathione peroxidase activity, Goserelin acetate, Bicalutamide.
Veröffentlicht
Ausgabe
Rubrik
Lizenz
Copyright (c) 2026 Wejdan Salman Hashim, Yasser A.H. Al-Issa
Dieses Werk steht unter der Lizenz Creative Commons Namensnennung 4.0 International.
Authors retain the copyright of their articles and grant the Functional Food Center (FFC) and its journals the right of first publication under the terms of the Creative Commons Attribution 4.0 International License.
This license permits unrestricted use, distribution, and reproduction in any medium, including commercial use, provided the original author(s) and source are properly credited. Authors may post and share their published work freely, provided that the original publication in this journal is acknowledged.
By submitting to this journal, authors confirm that their manuscripts are original, not under consideration elsewhere, and that they hold the necessary rights to grant this license. The Functional Food Center encourages open scientific exchange and allows derivative and extended works, provided attribution to the original publication is maintained.